幽门螺杆菌感染对使用非甾体抗炎药、抗血小板药、抗凝药、皮质类固醇和选择性5-羟色胺再摄取抑制剂患者消化性溃疡出血风险的贡献
这项回顾性队列研究纳入2004年1月至2014年12月经内镜诊断的1719例消化性溃疡患者,其中56.9%为溃疡出血病例,43.1%为无并发症溃疡对照。幽门螺杆菌感染增加使用非甾体抗炎药和阿司匹林患者的溃疡出血风险,在联合抗血小板治疗患者中风险最高。
要点
- 幽门螺杆菌感染增加非甾体抗炎药使用者溃疡出血风险(OR=2.91,95%CI=1.71-4.98)。
- 幽门螺杆菌感染增加阿司匹林使用者溃疡出血风险(OR=2.23,95%CI=1.52-3.28)。
- 幽门螺杆菌阳性联合抗血小板治疗患者溃疡出血风险最高(OR=8.43,95%CI=1.09-65.17)。
核心结论
- 幽门螺杆菌感染增加使用非甾体抗炎药、阿司匹林和非阿司匹林抗血小板药的消化性溃疡患者溃疡出血风险。
- 幽门螺杆菌阳性的联合抗血小板治疗患者溃疡出血风险最高。
研究设计与样本
- 回顾性队列研究,纳入2004年1月至2014年12月经内镜诊断的消化性溃疡患者1719例,其中男性占60%,年龄65.8±14.5岁。
- 56.9%为消化性溃疡出血病例,43.1%为无并发症消化性溃疡对照。
- 记录人口学特征、非甾体抗炎药、阿司匹林、非阿司匹林抗血小板药、抗凝药、选择性5-羟色胺再摄取抑制剂、质子泵抑制剂和皮质类固醇使用情况。
- 幽门螺杆菌状态通过组织学、快速尿素酶试验或血清学确定。
- 采用逻辑回归分析估计调整后的比值比(OR)。
主要发现
- 幽门螺杆菌感染增加非甾体抗炎药使用者溃疡出血风险(OR=2.91,95%CI=1.71-4.98)和阿司匹林使用者溃疡出血风险(OR=2.23,95%CI=1.52-3.28)。
- 幽门螺杆菌感染未增加抗凝药、选择性5-羟色胺再摄取抑制剂或皮质类固醇治疗患者的溃疡出血风险。
- 幽门螺杆菌阳性增加非阿司匹林抗血小板药使用者溃疡出血风险(OR=4.37,95%CI=1.28-14.99)。
- 幽门螺杆菌阳性增加阿司匹林/非甾体抗炎药联合使用者溃疡出血风险(OR=5.85,95%CI=1.68-20.36)。
- 幽门螺杆菌阳性增加联合抗血小板治疗使用者溃疡出血风险(OR=8.43,95%CI=1.09-65.17)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Nonsteroidal anti-inflammatory drugs, low-dose aspirin, non-aspirin antiplatelet agents, anticoagulants, selective serotonin reuptake inhibitors and corticosteroids increase the risk of gastroduodenal bleeding. AIM: To determine in a retrospective cohort study the contribution of Helicobacter pylori infection to the risk of peptic ulcer bleeding in patients taking these drugs. METHODS: Among patients with peptic ulcer disease diagnosed by endoscopy from 01/2004 to 12/2014 (N = 1719, 60% males, age 65.8 ± 14.5), 56.9% had peptic ulcer bleeding (cases) and 43.1% uncomplicated peptic ulcer disease (controls). Demographics, intake of nonsteroidal anti-inflammatory drugs, aspirin, non-aspirin antiplatelet agents, anticoagulants, selective serotonin reuptake inhibitors, proton pump inhibitors and corticosteroids were documented. H. pylori status was determined by histology, rapid urease test or serology. Adjusted odds ratios (OR) were estimated by logistic regression analysis. RESULTS: Helicobacter pylori infection increased the risk of peptic ulcer bleeding in nonsteroidal anti-inflammatory drug and aspirin users (OR = 2.91, 95% CI = 1.71-4.98 and OR = 2.23, 95% CI = 1.52-3.28, respectively), but not in patients on anticoagulants, selective serotonin reuptake inhibitor or corticosteroid therapy. H. pylori-positive status substantially increased the risk of peptic ulcer bleeding in patients on non-aspirin antiplatelet agents (OR = 4.37, 95% CI = 1.28-14.99), concomitant aspirin/nonsteroidal anti-inflammatory drug intake (OR = 5.85, 95% CI = 1.68-20.36) and combined antiplatelet therapy (OR = 8.43, 95% CI = 1.09-65.17). After further adjustment for proton pump inhibitor intake, H. pylori infection was still a risk factor for peptic ulcer bleeding in nonsteroidal anti-inflammatory drug and aspirin users. CONCLUSIONS: Helicobacter pylori infection increases the risk of peptic ulcer bleeding in peptic ulcer disease patients on nonsteroidal anti-inflammatory drugs, aspirin and non-aspirin antiplatelet agents. H. pylori-positive patients on combined antiplatelet therapy carry the highest risk for peptic ulcer bleeding.
引用
- Venerito M, Schneider C, Costanzo R, et al. Contribution of Helicobacter pylori infection to the risk of peptic ulcer bleeding in patients on nonsteroidal anti-inflammatory drugs, antiplatelet agents, anticoagulants, corticosteroids and selective serotonin reuptake inhibitors. Aliment Pharmacol Ther. 2018. PMID: 29655196. doi:10.1111/apt.14652
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。